Tedol

Quick links to important sections

Tedol

Selected form

Method of action: Antifungal Broad Spectrum

Treatment option: Dermatitis, Infection

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tedol

Property Description
Active ingredient Ketoconazole
Form Topical (Cream, Shampoo, Gel)
Pharmacological class Azole Antifungal / Imidazole Derivative
Common Use Treating Fungal and Yeast Infections
Origin Synthetic

Tedol is a trade name for a medicine containing the active substance Ketoconazole, which is classified as a synthetic antifungal agent. Ketoconazole is recognized as an imidazole derivative and belongs to the broader azole antifungal class of medications. This substance is recognized for its efficacy against various common pathogenic fungi and yeasts. Its role is to inhibit or neutralize mycoses (fungal infections), such as those causing skin scaling or itching.


Composition and Available Preparations of Ketoconazole

Tedol is a single-ingredient product of synthetic organic origin. Although the underlying active ingredient, Ketoconazole, was initially developed for oral tablets to address internal, systemic infections, its primary and most common application today is via the topical route of administration, as a topical preparation applied externally. These antifungals are used to stop the proliferation of organisms that infect the superficial layers of the body. These topical forms are typically formulated as a cream, gel, or medicated shampoo, utilizing a distinct base vehicle to ensure efficient contact with the infected tissue. Tedol preparations focus on topical formats intended for over-the-counter access for treating common external fungal conditions.


How Does Ketoconazole Generally Achieve Its Purpose?

The overarching purpose of Ketoconazole is the effective resolution of fungal infections by directly interfering with the viability of the fungal organism. The substance works by disrupting the physical structure of the fungal cell as a fungistatic agent. It operates by inhibiting the synthesis of ergosterol, a crucial lipid that the fungus requires to build and maintain its vital cell membrane, thereby preventing the organism from growing and spreading.

Regulatory References

  1. EMA Ketoconazole Topical Use Advice
  2. EMA Report on Azole Resistance

What side effects are possible with Tedol?

Possible Side Effects and Safety Information

The safety profile for topical Ketoconazole (Tedol) is primarily defined by local reactions at the application site, reflecting the minimal systemic absorption documented in regulatory studies. The low level of the active substance entering the bloodstream minimizes the potential for systemic adverse effects typically associated with oral antifungal therapy.

Frequency-Classified Adverse Reactions

Official regulatory documents classify adverse reactions based on their frequency in clinical use. These effects are generally grouped under Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions.

Classification Examples of Documented Reactions
Common Application site burning sensation, irritation, pruritus (itching), and erythema (redness).
Uncommon Folliculitis, contact dermatitis, skin peeling, skin pain, and changes in hair texture.
Rare/Not Known Hypersensitivity, urticaria (hives), angioedema (swelling of the face or throat), and anaphylactic reaction.

Documented Serious Reactions and Safety Notes

The official label lists serious adverse reactions classified as rare or not known frequency, including severe hypersensitivity reactions and, in extremely rare cases, angioedema or anaphylactic reaction, which are related to the body's immune system response.

For the topical form, systemic plasma concentrations are generally not detectable in adults. Local reactions such as burning and irritation may be more frequently observed at the start of treatment. Safety statements for pregnancy and lactation generally note the negligible absorption, though use is often advised only when potential benefits justify potential risks, consistent with regulatory guidelines.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the documented overdose manifestations and mandated emergency actions for Tedol (topical ketoconazole) as established in official government regulatory labeling.


Documented Overdose Manifestations

Since Tedol is a topical formulation, the officially documented manifestations are primarily localized or related to accidental intake.

  • Topical Over-application: Excessive use on the skin may lead to localized signs at the site of application. These include Erythema (redness of the skin), Oedema (swelling), and a Burning Sensation. These effects are generally expected to resolve after stopping treatment.
  • Systemic Manifestations: The regulatory profile for the topical product does not document specific severe systemic symptoms or signs, such as cardiac or neurological effects, following accidental overdose.

Required Emergency Actions

Emergency action is primarily required in the event of accidental oral ingestion of the topical product.

Overdose Scenario Required Action (As Stated in Official Labeling)
Accidental Ingestion Contact a healthcare provider or a Poison Control Center right away.
Life-Threatening Symptoms If the individual collapses, has a seizure, or is having trouble breathing, immediately call emergency services (e.g., 911).

Supportive Management

No specific antidote is documented for ketoconazole overdose. Treatment is defined as supportive and symptomatic in nature. For the shampoo formulation, regulatory advice specifically cautions against inducing emesis (vomiting) or gastric lavage to avoid the risk of aspiration.

Therapeutic Uses of Tedol

What Tedol Treats: Main Uses and Benefits

Topical ketoconazole (Tedol) is used across therapeutic domains where symptoms related to inflammatory or irritative states are driven by yeast or fungal overgrowth. This application is indicated for areas where supportive symptom management is appropriate to address groups of symptoms that may appear suddenly or fluctuate.


Key Therapeutic Domains

This medication is commonly used to help with conditions characterized by periods of heightened symptoms stemming from fungal infections. These include Tinea Corporis (ringworm of the body), Tinea Cruris (jock itch), Tinea Pedis (athlete's foot), Seborrheic Dermatitis (dandruff and scaling), and Pityriasis Versicolor (skin discoloration).

The medication is relevant for easing symptoms related to physical discomfort, specifically pronounced itching, scaling, and the appearance of scaly rashes. This supportive relief contributes to improved comfort during symptomatic periods by assisting with managing discomfort.

“This application may assist with easing distress related to visible skin symptoms and persistent pruritus during difficult episodes.”


Quick Fact: Relief for Itching

Quick Fact: Relief for Itching

Topical ketoconazole is often used during phases when symptoms become more noticeable, helping to address the common pattern of pruritus symptoms that may interfere with daily comfort in conditions like ringworm and seborrheic dermatitis.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility profile for Tedol (Topical Ketoconazole) is determined by the official standards of regulatory bodies, focusing on patient characteristics that either prohibit or restrict its use.

Eligibility Scope

Populations for whom use is contraindicated:

  • Persons with a known hypersensitivity or allergy to the active ingredient, ketoconazole, or to any excipient (inactive ingredient) in the specific product formulation.

Age-related eligibility rules:

  • Children under 12 years: The safety and effectiveness have not been established for most prescription-strength topical preparations in this age group, leading to restricted use.
  • Adults and Adolescents 12 years: Use is generally approved for labeled indications.

Condition-specific eligibility rules:

  • Hepatic or Renal Impairment: No label restriction is required due to the medicine's minimal systemic absorption, which distinguishes it from the oral form.

Pregnancy and lactation eligibility status:

  • Pregnancy (Category C): Use is restricted and should be considered only if the potential benefit justifies the potential risk.
  • Lactation: Use requires caution, as it is not known whether the drug is excreted in human milk following topical application.

Eligibility-related restrictions:

  • The product is strictly for external use only and must be restricted from ophthalmic (eye), oral, and intravaginal administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for topical ketoconazole (Tedol) establishes a specific interaction profile based on its route of administration and pharmacokinetics. Due to the minimal to non-detectable systemic absorption of the active substance after application to the skin, clinically significant systemic drug-drug interactions are not expected according to regulatory documents.

This low systemic exposure means that the numerous metabolic interactions, such as the inhibition of the CYP450 enzyme system, which are a major concern with the oral form of ketoconazole, are not applicable to this topical medicine. Consequently, formal systemic drug-drug contraindications are not documented in the official labeling.

Documented Localized Interaction Rule

The primary interaction described in regulatory labeling is localized and procedural, related to co-administration with other topical products. A mandatory timing rule is required when transitioning a patient from a prolonged treatment with a topical corticosteroid to Tedol. This procedure is intended to mitigate a potential symptom rebound effect upon corticosteroid withdrawal.

  • Timing Requirement: The label stipulates that when co-administering, the topical corticosteroid must be applied in the morning, and the ketoconazole product must be applied in the evening, followed by a gradual reduction and cessation of the corticosteroid over two to three weeks.
  • Other Interactions: No specific interaction cautions are officially documented in regulatory information for the topical formulation regarding food, alcohol, or herbal products.

Mechanism of Action

Molecular Mechanism: Inhibition of Fungal Sterol Synthesis

Tedol (Ketoconazole) acts by targeting the structures and synthesis pathways of the fungal organism, leading to compromised cell viability.

Ketoconazole functions as an inhibitor of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51). This inhibition directly blocks a key step in the fungal sterol biosynthesis pathway, which is necessary for creating the essential lipid ergosterol. The resulting physiological effect is the depletion of this vital lipid, initiating a cascade of cellular failure.

This molecular interaction triggers the mechanistic cascade of cell membrane destabilization. The absence of sufficient ergosterol, combined with the accumulation of toxic intermediate lipids (14-methyl sterols), critically compromises the fungal cell membrane's structure and permeability. This instability leads to the functional collapse of the cell's transport and signaling systems, thereby leading the organism into a state of growth arrest.

The drug's action is characterized as fungistatic because its primary physiological consequence is to halt the proliferation of the fungal organism, rather than immediately kill it. The overall efficacy is concentration-dependent, meaning the speed of the organism's growth arrest is dictated by the drug concentration achieved at the localized tissue site.

Dosage and Administration Information

Administration Guidelines: Official Instructions for Tedol

Tedol (ketoconazole topical) is a medicine intended for cutaneous administration only and must not be used orally, ophthalmicly, or intravaginally. The specific application frequency and treatment duration are established for the medicine's form and the target condition.


Official Dosing and Duration

Preparation (2% Strength) Application Frequency Course Duration (General)
Cream (for Tinea/Candidiasis) Once Daily 2 to 4 weeks
Cream/Foam (for Seborrheic Dermatitis) Twice Daily Up to 4 weeks
Gel (for Seborrheic Dermatitis) Once Daily 2 weeks
Shampoo (for Seborrheic Dermatitis) Twice Weekly 2 to 4 weeks

Key Procedural Steps

The following instructions detail the proper administration method:

  • Application Coverage: The product must be applied to the entire affected area and the immediate surrounding skin area.
  • Shampoo Contact Time: When using the 2% shampoo, it must be worked into a lather and remain in contact with the skin or scalp for a period of 3 to 5 minutes before being rinsed off thoroughly.
  • Post-Application Constraint (Gel): Following the application of the 2% gel, the treated area should not be washed for at least 3 hours.
  • Preparation Requirement (Foam/Gel): Due to the components of the foam and gel, they should be dispensed onto a cool surface, such as the container cap, to prevent immediate melting before application.
  • Age-Group Rules: Dosage for adolescents (12 years of age and older) is consistent with adult regimens for the gel and foam preparations. Use in children under 12 is determined by a healthcare provider.

This structured approach ensures the medication is used according to the precise methods and timelines established for this treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tedol

Evidence Base for Seborrheic Dermatitis and Scalp Scaling

The research on topical ketoconazole for seborrheic dermatitis was primarily based on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined outcomes related to inflammatory or irritative states and were designed to evaluate how symptoms change over defined time intervals. Populations studied generally included adults and adolescents (aged ge 12 years).

Studies report measurements of changes related to objective signs like redness (erythema) and scaling severity. Research provides insight into short-term changes, with findings describing patterns observed in the measured outcomes, typically over the course of 2 to 4 weeks. However, long-term outcomes are not fully characterized by controlled trials, and evidence is limited regarding the durability of the outcomes following the end of the short treatment course.


Evidence Base for Tinea Infections (Ringworm and Jock Itch)

Short-term clinical trials have evaluated topical ketoconazole for infections such as Tinea Corporis and Tinea Cruris. The focus of these studies was on assessing both clinical signs and measurements related to the presence of the causative fungal organisms (mycological status).

Studies report how symptoms evolved in the observed populations, tracking measurements of signs like scaling, redness, and inflammation. Evidence is generally available for short-term outcomes achieved over the typical 2 to 4-week treatment and follow-up window. Comparative evidence is lacking for direct comparisons against all available alternative topical antifungals using identical study designs.


Evidence in Specific Patient Populations and Uncertainty

The main efficacy trials primarily included adults and adolescents. Data for certain groups, such as children under 12 years of age, remain insufficient, and the research provides limited insight into these specific populations. Studies focused on individuals with complex or severe co-morbidities are typically excluded.

The research base has several noted limitations. Follow-up durations were limited in most efficacy studies, which means there is insufficient data regarding sustained symptom control over months or years. Research exploring maintenance strategies related to recurrence of conditions like seborrheic dermatitis is ongoing, and certainty remains low in these specific areas.

Key Studies & References

  1. Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis
  2. NCT01110330: An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis

Frequently Asked Questions (FAQ)

Common questions about Tedol (FAQ)

Q: Does Tedol cause drowsiness or make you tired?

A: According to official product information, topical Tedol is not typically associated with causing drowsiness or fatigue. The product information indicates systemic absorption is minimal. However, dizziness has been reported rarely as an adverse reaction.


Q: Does taking Tedol affect my ability to drive?

A: Regulatory documents do not include specific cautions against driving while using topical Tedol. If side effects such as dizziness or nervous system effects are experienced, regulatory information suggests caution may be necessary.


Q: Is it normal to feel a bit dizzy after starting Tedol?

A: Dizziness is documented in official safety information as a rare adverse reaction to topical ketoconazole. If dizziness or other unusual reactions occur, regulatory guidance suggests consulting a healthcare provider.


Q: Are headaches a potential side effect of Tedol?

A: Headaches have been reported as a side effect following the use of topical ketoconazole. Although they may be reported, official safety data typically does not list them among the most common adverse reactions reported for topical formulations.


Q: Is it safe to drink coffee while taking Tedol?

A: Official regulatory documents do not list any specific interaction cautions regarding the consumption of coffee or caffeine products while using topical Tedol. Since the medicine is minimally absorbed through the skin, dietary restrictions are not generally specified in regulatory information for this topical medicine.


Q: What should I do if I miss a dose of Tedol?

A: If you forget to apply a dose of Tedol, you should skip that missed dose and continue with your regular application schedule. The product information states that extra medication should not be used to compensate for a missed dose.


Q: Is there a generic version of Tedol available?

A: Yes, the active ingredient in Tedol, which is ketoconazole, is available in generic topical formulations. These generic versions are commonly available in various forms, including creams and shampoos.


Q: Are there different strengths or versions of the Tedol pill?

A: Tedol is a trade name for a topical medicine applied to the skin, available as a cream, gel, foam, or shampoo. These topical products are commonly available in different concentrations, such as 1% and 2% strengths.


Q: Does Tedol affect blood pressure?

A: According to official safety data, effects on the body's systems, such as changes in blood pressure, are not expected with topical Tedol. This is consistent with the minimal absorption of the medicine into the bloodstream after skin application.


Q: Does Tedol interfere with birth control pills?

A: Topical Tedol has minimal systemic absorption. Therefore, the medicine is not expected to interfere with the effectiveness of hormonal birth control pills or other systemic contraceptives.


Q: Does Tedol lose its effectiveness over time?

A: The medication is required by regulatory standards to maintain its full strength and quality until the expiration date printed on the label when the medication is stored according to the instructions on the label.


Q: Are there common skin reactions associated with Tedol?

A: The most commonly reported skin reactions include a burning sensation, irritation, itching (pruritus), and redness (erythema). These reactions have been documented at the application site.


Q: Why do some people say Tedol is not suitable for them?

A: Official eligibility rules state that Tedol is not suitable for individuals who have a known hypersensitivity or allergy to the active ingredient, ketoconazole, or to any of the inactive ingredients used in the product formulation.


Q: What happens if you suddenly stop taking Tedol?

A: Stopping the medication early may result in the recurrence of the infection. In patients transitioning from a prolonged topical corticosteroid treatment, abrupt discontinuation has been associated with a symptom rebound effect.


Q: Does Tedol make other medications less effective?

A: Due to its minimal systemic absorption, topical Tedol is not expected to cause clinically significant drug-drug interactions with other systemic medicines. Regulatory labeling specifies a procedural timing rule when transitioning from a prolonged topical corticosteroid treatment to this product.


Q: Can Tedol be taken with common multivitamins?

A: Common multivitamins are generally acceptable to use while applying topical Tedol. Minimal absorption of the medicine indicates that interference with the absorption or action of standard vitamin supplements is not anticipated.

How should Tedol be stored and disposed of?

Official Storage and Disposal Profile

This profile is based on mandatory regulatory requirements for prescription drugs, ensuring the medication's quality, strength, and security are maintained throughout its labeled shelf life.

Storage Category Official Requirement
Temperature Control Store at the temperature specified on the label, often defined as controlled room temperature (15 C to 30 C), to prevent loss of quality.
Stability Do not use the medication after the expiration date printed on the label. Stability testing ensures the drug’s integrity up to this date.
Environmental Protection Keep the medication in its original, tightly closed container to protect it from moisture and light, as indicated by stability data.
Security and Access Keep all medication stored securely and out of the reach of children to prevent accidental ingestion or unauthorized access.
Disposal Ultimate users must dispose of unused, unwanted, or expired medication through an authorized collector or an approved official take-back program. Hazardous waste pharmaceuticals must be managed according to environmental regulations (e.g., RCRA).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tedol found in:

A-Z Index: